Helping young people who inject drugs start treatment for Hepatitis C
A Randomized Trial to Test the Efficacy of a Partner Navigation Intervention for HCV Treatment Among Young Adult People Who Inject Drugs
This study tests a new support program to help young adults who inject drugs start treatment for Hepatitis C and see if it works better than regular care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 500 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University of California, San Francisco Academic / other |
| Locations | 1 site (San Francisco, California) |
| Trial ID | NCT06179498 on ClinicalTrials.gov |
What this trial studies
This study evaluates a behavioral intervention designed to increase the initiation of Hepatitis C treatment among young adults who inject drugs. It involves a randomized controlled trial with 250 participants, including individuals diagnosed with Hepatitis C and their primary injecting partners. The intervention consists of two sessions aimed at providing support and resources to encourage treatment initiation, compared to standard care. The study focuses on young people aged 18-30 to address a critical gap in treatment uptake within this population.
Who should consider this trial
Good fit: Ideal candidates are young adults aged 18-30 who have recently been diagnosed with Hepatitis C and have a primary injecting partner.
Not a fit: Patients who do not inject drugs or those who are not recently diagnosed with Hepatitis C may not benefit from this study.
Why it matters
Potential benefit: If successful, this intervention could significantly improve treatment initiation rates for Hepatitis C among young people who inject drugs.
How similar studies have performed: Other studies have shown that behavioral interventions can effectively improve treatment uptake in similar populations, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Self report injecting drugs in the past month * Self report a primary injecting partner (currently inject drugs together) * HCV infection identified at partnering community-based clinical site
Where this trial is running
San Francisco, California
- University of California, San Francisco — San Francisco, California, United States (Recruiting)
Study contacts
- Principal investigator: Meghan D Morris, MPH, PhD — University of California, San Francisco
- Study coordinator: Meghan D Morris, MPH, PhD
- Email: meghan.morris@ucsf.edu
- Phone: 415-574-0651
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.